Faslodex (fulvestrant) 250 mg/5 mL solution for injection, 2 pre-filled syringes (AstraZeneca) Breast cancer. Delivery of medications from Europe and beyond within 4-5 days, storage conditions are met, payment upon receipt. Order by calling +380996042415, Viber, or WhatsApp.

Fazlodex indications:

• as monotherapy for the treatment of locally enlarged or metastatic breast cancer with estrogen-positive receptors in postmenopausal women:
• endocrine therapy has not been discontinued before, or
• Illness relapses within an hour either after adjuvant antiestrogenic therapy or disease progression during antiestrogenic therapy;
• in combination with palbociclib for the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in women, which removes the anterior endocrine therapy (division “Pharmacodynamics”).

In premenopausal or perimenopausal women, treatment is combined with palbociclib should be carried out in combination with a luteinizing hormone-releasing hormone (LHRH) agonist.

Dozuvannya

Mature women (including those of the summer age)

It is recommended to set the dose to 500 mg, to stabilize at an interval of one month, and two days after the first injection, an additional dose of 500 mg is administered.

If the medicinal drug Faslodex is used in combination with Palbociclib is also amazing. Brief description of palbociclib.

Women in the pre-/perimenopausal period before and during the period of combination therapy with the drug Faslodex and palbociclib prevent the agonism of LHRH (luteinizing hormone releasing hormone) consistent with local standards of clinical practice.